Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

20 February 2020

2020: The Investor Year of Action on Antibiotics?

Vibeka Mair of the Responsible Investor writes about a new collaboration involving the Access to Medicine Foundation to galvanise investor efforts to address AMR.

Direct links

Read the full article

At launch of the new Antimicrobial Resistance Benchmark during a high-level panel discussion at the 2020 WEF Annual Meeting, a new collaboration between the UK Government, the Access to Medicine Foundation, the FAIRR Initiative and the Principles for Responsible Investment was announced.

The article shines light on the aim of the initiative which is to encourage and guide investors to use an “AMR lens” when making decisions and engaging with companies. 

In the article Alice Evans, Co-Head of the Responsible Investment team at BMO Global Asset Management, is quoted saying that "the Access to Medicine Foundation’s AMR Benchmark is a useful tool to analyse pharmaceutical companies’ strategies to combat AMR."

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved